Pfizer Tuas Expansion

C2D Solutions is proud to have contributed to the development of Pfizer’s new Active Pharmaceutical Ingredient (API) manufacturing facility in Tuas Biomedical Park, Singapore. This state-of-the-art, 429,000 square foot plant represents a significant $1 billion investment by Pfizer and is set to produce APIs for oncology, pain, and antibiotic medicines for global distribution.

Our team provided comprehensive professional and fire engineering services throughout the project’s lifecycle. From the initial design phase to final implementation, we ensured that the facility met stringent safety standards and adhered to local regulatory requirements. Our fire engineering solutions were tailored to the unique needs of pharmaceutical manufacturing environments, incorporating advanced technologies and best practices to safeguard both personnel and assets.

The successful completion of this project not only enhances Pfizer’s manufacturing capabilities but also contributes to Singapore’s standing as a leading biomedical sciences hub. We are honored to have been part of this landmark project and remain committed to delivering engineering excellence in the biomedical sector.

News References:
straitstimes.com

Channel News Asia